| Literature DB >> 32505806 |
Luigi Mele1, Vitale Del Vecchio1, Davide Liccardo1, Claudia Prisco2, Melanie Schwerdtfeger3, Nirmal Robinson4, Vincenzo Desiderio1, Virginia Tirino1, Gianpaolo Papaccio5, Marcella La Noce1.
Abstract
Autophagy is a self-degradative cellular process, involved in stress response such as starvation, hypoxia, and oxidative stress. This mechanism balances macro-molecule recycling to regulate cell homeostasis. In cancer, autophagy play a role in the development and progression, while several studies describe it as one of the key processes in drug resistance. In the last years, in addition to standard anti-cancer treatments such as chemotherapies and irradiation, targeted therapy became one of the most adopted strategies in clinical practices, mainly due to high specificity and reduced side effects. However, similar to standard treatments, drug resistance is the main challenge in most patients. Here, we summarize recent studies that investigated the role of autophagy in drug resistance after targeted therapy in different types of cancers. We highlight positive results and limitations of pre-clinical and clinical studies in which autophagy inhibitors are used in combination with targeted therapies.Entities:
Keywords: Autophagy; Drug resistance; Monoclonal antibodies; Targeted therapy; Tyrosine kinase inhibitors
Year: 2020 PMID: 32505806 DOI: 10.1016/j.ctrv.2020.102043
Source DB: PubMed Journal: Cancer Treat Rev ISSN: 0305-7372 Impact factor: 12.111